Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 695 • 2016 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Xenofon Baraliakos¹, Michael Schiff², Karel Pavelka³, Ruvie Martin⁴, Brian Porter⁴ and Corine Gaillez⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of Colorado, School of Medicine, Denver, CO, ³Institute and Cliníc of Rheumatology, Charles University, Prague, Czech Republic, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The assessment of achieving, maintaining, and improving clinical response to biologics in Ankylosing Spondylitis (AS) is part of treat-to-target recommendations aimed at optimizing treatment…
Abstract Number: 1044 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Désirée van der Heijde², Xenofon Baraliakos³, Atul A. Deodhar⁴, Matt Brown⁵, Sarah Sherlock⁶, David Li⁷, Dona Fleishaker⁸ and Thijs Hendrikx⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor. Minimum clinically important differences (MCID) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI SI joint and spine…
Abstract Number: 1916 • 2016 ACR/ARHP Annual Meeting
Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Diahann Jansen¹, Elizabeth Klinken¹, Hendrik Nel², Soi Cheng Law², Helen Benham^3,4,5, Lisa Cummins⁶, Matthew Brown⁷, Tony Kenna², Ligong Liu⁸, David Fairlie⁸, Jamie Rossjohn^9,10,11, Mark Morrison³, Ranjeny Thomas³, Paraic O Cuiv¹, James McCluskey¹² and Alexandra Corbett¹², ¹The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Australia, ⁴University of Queensland School of Medicine, Brisbane, Australia, ⁵Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Woolloongabba, Australia, ⁷Queensland University of Technology, Brisbane, Australia, ⁸Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, ⁹Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ¹⁰Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ¹¹Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, ¹²Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia
Background/Purpose: Mucosal associated invariant T (MAIT) cells are an innate-like lymphocyte population predominant at mucosal sites, which express a semi-invariant T cell receptor restricted to…
Abstract Number: 2756 • 2016 ACR/ARHP Annual Meeting
Gender Differences in Body Composition with Dual-Energy X-Ray Absorptiometry in TNF-α Blocker Naive Ankylosing Spondylitis Patients
Sebastián Ibáñez^1,2, Ingrid M. Visman³, Christiaan van Denderen³, Willem F. Lems^4,5, M. Nurmohamed^4,6 and Irene van der Horst - Bruinsma⁴, ¹Reumatología, Clínica Alemana de Santiago, Santiago, Chile, ²Reumatología, Hospital Padre Hurtado, Santiago, Chile, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, New Caledonia, ⁶Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands
Background/Purpose: Data on body composition (BC) in Ankylosing Spondylitis (AS) are sparse and controversial. Female AS patients have less response to TNF-α blockers and a…
Abstract Number: 696 • 2016 ACR/ARHP Annual Meeting
Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab
S.C. Heslinga^1,2, M. T. Nurmohamed^1,3, A. H. Gerards⁴, E. Griep⁵, C. Koehorst⁶, M. R. Kok⁷, A. Schilder⁸, M. Verhoef⁹ and I.E. Van der Horst - Bruinsma^1,2, ¹Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Antonius Hospital, Sneek, Netherlands, ⁶Rheumatology, Gelre Hospital, Apeldoorn, Netherlands, ⁷Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁸Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁹Immunology, MSD the Netherlands, Haarlem, Netherlands
Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective…
Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…
Abstract Number: 1956 • 2016 ACR/ARHP Annual Meeting
High Dose Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor Use Results in Less Radiographic Progression in Ankylosing Spondylitis – a Longitudinal Analysis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Thomas Learch⁴, Matthew Brown⁵, Mohammad H. Rahbar³, Michael Weisman⁶ and Michael Ward⁷, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁵Queensland University of Technology, Brisbane, Australia, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: Over the last decade, the disease modifying effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor inhibitors (TNFi) have resulted in conflicting studies. …
Abstract Number: 2764 • 2016 ACR/ARHP Annual Meeting
Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample
Vibeke Strand¹, R Alten², Philip G. Conaghan³, Louise Huneault⁴, Emma Sullivan⁵, Stuart Blackburn⁵, Haijun Tian⁶, Kunal Gandhi⁶, Steffen Jugl⁷, Hedley Hamilton⁸ and Raj Mahapatra⁹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Adelphi Real World, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸any-3 Ltd, London, United Kingdom, ⁹gplus, London, United Kingdom
Unhappiness is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample Background/Purpose:…
Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Jeffrey R. Curtis¹, Dirk Elewaut², Su Chen³, Maja Hojnik⁴, Navit Naveh⁵ and Jaclyn K. Anderson³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵AbbVie, Hod HaSharon, Israel
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
Abstract Number: 1279 • 2016 ACR/ARHP Annual Meeting
Imaging of Ankylosing Spondylitis By [18f]Fluoride PET-CT to Assess Bone Formation Activity and to Monitor Anti-TNF Therapy
Stefan Bruijnen¹, Nicki Verweij², Leonie van Duivenvoorde³, Dominique Baeten⁴, Christiaan van Denderen⁵, Joost Bot⁶, Otto Hoekstra⁷, Pieter Raijmakers⁶, Irene van der Horst - Bruinsma⁸ and Conny van der Laken², ¹Dept. of Rheumtaology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ²Dept. of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵READE, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁶Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁷Nuclear medicine and PET research, VU University Medical Center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Bone formation is an important hallmark of ankylosing spondylitis (AS). Recently, we demonstrated that axial bone formation activity in AS patients can be visualized…
Abstract Number: 2003 • 2016 ACR/ARHP Annual Meeting
Validation of the ASAS Health Index: Results of a Multicenter International Study in 23 Countries
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Jürgen Braun¹ and ASAS HI international validation study, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The ASAS Health Index (ASAS HI) was developed to measure functioning and health in patients with spondyloarthritis (SpA) aiming to better define the impact…
Abstract Number: 2777 • 2016 ACR/ARHP Annual Meeting
Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?
Kemal Erol¹, Gizem Cengiz¹, Kevser Gok¹, Gamze Kilic², Erkan Kilic³ and Salih Ozgocmen¹, ¹Dept.PRM, Erciyes University, Faculty of Medicine, Division of Rheumatology, Kayseri, Turkey, ²Afyon Kocatepe University, Faculty of Medicine, Dept.PRM, Afyon, Turkey, ³Afyonkarahisar Kocatepe State Hospital, Division of Rheumatology, Afyon, Turkey
Background/Purpose: Spondyloarthropathies include a group of disease which have similar clinical, radiographic and genetic features. Uveitis, psoriasis (PsO) and inflammatory bowel disease (IBD) are common…
Abstract Number: 5L • 2015 ACR/ARHP Annual Meeting
Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Atul A Deodhar², James C Wei³, Edit Drescher⁴, Dona Fleishaker⁵, Thijs Hendrikx⁶, David Li⁶, Sujatha Menon⁵ and Keith S Kanik⁵, ¹Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: This was the first investigation of the effects of tofacitinib (TOFA) in adult patients (pts) with active ankylosing spondylitis (AS). TOFA is an oral…
Abstract Number: 6L • 2015 ACR/ARHP Annual Meeting
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
Xenofon Baraliakos¹, Atul A. Deodhar², Jürgen Braun¹, Dominique Baeten³, Maxime Dougados⁴, Joachim Sieper⁵, Paul Emery⁶, Aimee Readie⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁸, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Hospital Cochin, Descartes Univ, Paris, France, ⁵University Hospital Charité, Berlin, Germany, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the MEASURE 1 trial (NCT01358175), secukinumab significantly improved the signs and symptoms of patients (pts) with active ankylosing spondylitis (AS) over 52 weeks…
Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].